Reputation and Precedent in the Bevacizumab Decision

The authors discuss the FDA’s decision to withdraw bevacizumab’s (Avastin) accelerated approval for metastatic breast cancer after confirmatory trials failed to show the expected benefit, arguing that the decision was appropriate and consistent with the regulatory framework for accelerated approval.